Development and validation of a new LC–MS/MS method for the determination of mefatinib in human plasma and its first application in pharmacokinetic studies ...

• Main Authors: Xu, Yichao, Chen, Jinliang, Shao, Rong, Ruan, Zourong, Jiang, Bo, Lou, Honggang
• Format: Article in Journal/Newspaper
• Language: unknown
• Published: figshare 2022
• Subjects: Biochemistry; Space Science; Medicine; Cell Biology; Genetics; FOS Biological sciences; Biological Sciences not elsewhere classified; Developmental Biology; Infectious Diseases; FOS Health sciences; Northern Goshawk
• Online Access: https://dx.doi.org/10.6084/m9.figshare.c.6299923; https://springernature.figshare.com/collections/Development_and_validation_of_a_new_LC_MS_MS_method_for_the_determination_of_mefatinib_in_human_plasma_and_its_first_application_in_pharmacokinetic_studies/6299923

Abstract Mefatinib (MET306) is a novel second-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) designed to address the highly unmet clinical need of gefitinib-induced resistance and irreversibly bind to mutated tyrosine kinase domain of EGFR and human epidermal growth factor receptor 2 (HER2). In this study, a liquid chromatography–tandem mass spectrometry method was established and validated for determining MET306 in non-small cell lung cancer patients and a backpropagation artificial neural network was developed and constructed to predict the pharmacokinetic process. The mobile phase was water containing 5 mM ammonium acetate and acetonitrile at a flow rate of 0.3 mL min−1, within a 4.5 min run time. MET306 was separated on a Hypersil Gold-C18 at 40 °C and subjected to mass analysis using positive electrospray ionization. A total of 524 data were used as development groups and 145 data were used as testing groups. The final established Northern Goshawk ...